Scully, Scott, Murphy & Presser, P.C.
Kinase inhibitor against wild-type and mutant EGFR
The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation.
PRECEDO PHARMACEUTICALS CO., LTD.
A A C
A61P A61K C07D
inventional inventional inventional
Hong Li Xixiang Fengming Beilei Qingsong Chen Wenchao Jing Kailin Cheng Ziping Aoli
Wu Wang Li Zou Wang Liu Hu Wang Liu Yu Chen Qi Wang